JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates

GSK is maintaining its strategic direction during Day 2 of the J.P. Morgan Healthcare Conference (JPM26), as highlighted in live coverage12.

AstraZeneca reported growth to 37 late-stage molecules or label expansions in 2025 (up from 27 in 2021), with key programs like oral PCSK9 med laroprovstat and ADC sonesitatug vedotin, and acquired Modella AI to boost oncology AI applications1.

Novo Nordisk enters 2026 post-restructuring with Martin Holst Lange as CSO, holding 200 meetings at JPM focused on metabolic innovations1.

Amgen advances six global phase 3 studies for obesity drug MariTide, confident in its maintenance dosing efficacy1.

Live blogs from Fierce Biotech and Fierce Pharma provide ongoing Day 2 updates on biopharma presentations and deals in San Francisco12.

Sources:

1. https://www.fiercebiotech.com/biotech/fierce-biotechs-jpm26-tracker-day-2

2. https://www.fiercepharma.com/pharma/fierce-pharmas-jpm26-tracker-day-2